How a Drugmaker Profited by Slow-Walking a Promising HIV Therapy
In 2004, Gilead Sciences decided to stop pursuing a new HIV drug. The public explanation was that it wasn’t sufficiently different from an existing treatment...
U.S. loses key patent case on rights to HIV prevention drugs
A federal jury has found that the federal government did not have an ownership claim to lucrative drugs to prevent HIV that are sold by...
‘Miracle’ cystic fibrosis drug kept out of reach in developing countries VIEW
An analysis led by researchers in Britain found that a year’s supply of the drug, Trikafta, could be manufactured at an estimated cost of just...
How a drug company made $114 billion by gaming the U.S. patent system VIEW
In 2016, a blockbuster drug called Humira was poised to become a lot less valuable.
How a sprawling hospital chain ignited its own staffing crisis VIEW
Ascension spent years reducing its staffing levels in an effort to improve profitability, even though it's a nonprofit with nearly $18 billion of cash reserves.
Democrats’ long-sought plan for lowering drug costs is at hand
Democrats are on the verge of passing a broad budget bill that would lower drug costs and deliver President Joe Biden a political victory that...